Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis

ClinicalTrials.gov ID: NCT00761657

Public ClinicalTrials.gov record NCT00761657. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Single-blind, Placebo-controlled, 4-Week Treatment Study of the Safety and Biologic Activity of Escalating Multiple Oral Doses of FG-4592 in Subjects With Chronic Kidney Disease Not Requiring Dialysis

Study identification

NCT ID: NCT00761657
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Kyntra Bio; Industry
Enrollment: 117 participants

Conditions and interventions

Conditions

Interventions

Roxadustat Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 31, 2006
Primary completion: Jun 20, 2010
Completion: Jun 20, 2010
Last update posted: Nov 18, 2021

2006 – 2010

United States locations

U.S. sites: 34
U.S. states: 21
U.S. cities: 34

Facility	City	State	ZIP	Site status
Not listed	Peoria	Arizona	85381	—
Not listed	Tempe	Arizona	85284	—
Not listed	Los Angeles	California	90095	—
Not listed	Mission Viejo	California	92691	—
Not listed	Sacramento	California	95825	—
Not listed	San Diego	California	92123	—
Not listed	Whittier	California	90603	—
Not listed	Arvada	Colorado	80002	—
Not listed	Westminster	Colorado	80031	—
Not listed	Middlebury	Connecticut	06762	—
Not listed	Ocala	Florida	34471	—
Not listed	Panama City	Florida	32401	—
Not listed	Pembroke Pines	Florida	33028	—
Not listed	Tampa	Florida	33614	—
Not listed	Augusta	Georgia	30901	—
Not listed	Chicago	Illinois	60616	—
Not listed	Evergreen Park	Illinois	60805	—
Not listed	Wichita	Kansas	67214	—
Not listed	Louisville	Kentucky	40202	—
Not listed	Baton Rouge	Louisiana	70809	—
Not listed	Shreveport	Louisiana	71101	—
Not listed	Detroit	Michigan	48236	—
Not listed	Lincoln	Nebraska	68510	—
Not listed	Las Vegas	Nevada	89106	—
Not listed	Flushing	New York	11355	—
Not listed	Winston-Salem	North Carolina	27103	—
Not listed	Cleveland	Ohio	44109	—
Not listed	Toledo	Ohio	43606	—
Not listed	Medford	Oregon	97504	—
Not listed	Wynnewood	Pennsylvania	19096	—
Not listed	Columbia	South Carolina	29203	—
Not listed	Orangeburg	South Carolina	29118	—
Not listed	Chattanooga	Tennessee	37404	—
Not listed	Houston	Texas	77036	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00761657, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 18, 2021 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00761657 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →